Drug
Granisetron Transdermal Patch clinical trials
- studies test it
- 5
- open now
- 1
- in phase 3
- 1
- first study started
- 2012
Keep track of what changes. Save the Granisetron Transdermal Patch studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2012 (2)
| Year | Studies |
|---|---|
| 2012 | 2 |
| 2020 | 1 |
| 2021 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 3
- 1
- Phase 4
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 2 · Other 3
Kyowa Kirin Pharmaceutical Development Ltd (1) · Kyowa Kirin, Inc. (1) · University of Illinois at Chicago (1) · University of Southern California (1) · Fudan University (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses Granisetron Transdermal Patch is read from its arms, and is right about nine times in ten.
Testing it · 5
- BMT-08: A Comparative Effectiveness Study of Transdermal Granisetron to OndansetronRecruitingPhase 4University of Illinois at ChicagoNCT04150614Written as Granisetron Transdermal Patch
- Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 13 to 17 YearsCompletedPhase 1Kyowa Kirin Pharmaceutical Development LtdNCT01596400Written as granisetron transdermal system
- Study to Assess Bioequivalence and Adhesion Properties Between Two Granisetron Transdermal Patches.CompletedPhase 1Kyowa Kirin, Inc.NCT05027646Written as Sancuso - Part 1
- Granisetron Transdermal Patch for Prophylaxis of Delayed CINVStatus unknownPhase 3Fudan UniversityNCT04912271Written as Granisetron transdermal patch
- Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing ChemotherapyTerminatedPhase 1University of Southern CaliforniaNCT01649258Written as granisetron transdermal system